What is Hormone Replacement Therapy?
Hormone Replacement Therapy (HRT) — now more precisely referred to in clinical literature as Menopausal Hormone Therapy (MHT) when discussing estrogen-based treatment — is a medical intervention that restores hormones the body stops producing at sufficient levels, most commonly estrogen, progesterone, and testosterone. For women, HRT typically addresses the hormonal decline associated with perimenopause and menopause, treating symptoms like hot flashes, night sweats, sleep disruption, and bone density loss. For men, hormone therapy most often takes the form of Testosterone Replacement Therapy (TRT), prescribed for clinically diagnosed hypogonadism or age-related testosterone decline. Formulations range from oral tablets and transdermal patches to gels, injectables, and implants, each carrying different risk and effectiveness profiles depending on the individual patient.
In the United States in 2026, hormone replacement therapy sits at a genuine inflection point. The FDA’s November 2025 decision to recommend removing the long-standing boxed warning on menopausal hormone therapy — a warning that had suppressed prescribing for over two decades following the 2002 Women’s Health Initiative study — has triggered a measurable resurgence in both patient demand and physician confidence. At the same time, testosterone prescribing has surged among American men, and a new Department of Defense screening mandate has pushed hormone health into national headlines. This report compiles the latest verified 2026 data on HRT usage, market size, benefits, risks, and access across the US healthcare system.
Interesting Facts About Hormone Replacement Therapy 2026
| Fact Category | Statistic | Details |
|---|---|---|
| US Testosterone Prescriptions (2024) | 11+ million | Up from ~7.3 million in 2019, a 50% increase |
| FDA Boxed Warning Status | Removed November 2025 | Applied to estrogen-based menopausal hormone therapy |
| US HRT Market Value (2026) | ~$27 billion (global) | North America holds roughly 38.6% of global revenue |
| US-Specific HRT Market (2022) | $7.76 billion | Projected to reach $12.57 billion by 2030 |
| Postmenopausal Women Who Have Used HRT | ~Half | NIH estimates roughly half have tried HRT at least once |
| US Women Currently Peri/Menopausal | Tens of millions | Roughly 1.3 million enter menopause annually |
| Men Over 45 with Hypogonadism | ~40% | Rising to nearly 50% by the 80s age bracket |
| New Non-Hormonal Drug Approved (2025) | Elinzanetant (Lynkuet) | FDA-approved October 24, 2025 for hot flashes |
| Men on Testosterone Without Formal Diagnosis | Up to 1/3 | Per American Urological Association guidance |
| Projected Global HRT Market by 2033 | $39.4–$42.3 billion | Multiple market research estimates converge in this range |
Data Source: FDA Drug Alerts, Grand View Research, CBS News prescription data, SingleCare, American Urological Association, NIH
The removal of the FDA’s boxed warning in November 2025 stands as the single most consequential statistic on this list, because it directly explains the acceleration in nearly every other HRT metric tracked for 2026. That warning, a legacy of the 2002 Women’s Health Initiative findings, had led physicians to under-prescribe menopausal hormone therapy for over twenty years even to women who would clinically benefit, and its removal has already begun reshaping prescribing behavior across the country. Combined with the new FDA approval of elinzanetant as a non-hormonal alternative, American women in 2026 have access to a genuinely broader and better-supported treatment landscape than at any point since the early 2000s.
On the male side, the jump from 7.3 million to over 11 million annual testosterone prescriptions between 2019 and 2024 reflects a parallel, if distinct, cultural and clinical shift toward treating hormone health as a mainstream men’s wellness category rather than a niche urology issue. With the US-specific HRT market valued at $7.76 billion in 2022 and projected to nearly double by 2030, and the broader global market approaching $27 billion in 2026, hormone replacement therapy has firmly established itself as one of the fastest-growing segments of the American pharmaceutical and telehealth economy.
HRT Usage & Prescribing Statistics in US 2026
| Metric | Figure | Detail |
|---|---|---|
| Postmenopausal Women Who Have Used HRT | ~50% | At least once in their lifetime, per NIH data |
| Women Currently Using HRT (Estimated) | Millions | Precise national figure not centrally tracked, unlike UK NHS data |
| Recommended HRT Initiation Window | Within 10 years of menopause onset, or before age 60 | Per current NIH/FDA guidance |
| Average Age of Menopause (US) | 51–52 years | Confirmed by NIH StatPearls, March 2026 |
| Average Perimenopause Duration | 4–10 years | Can extend up to 14 years in some cases |
| US Women Reaching Menopause Daily | ~6,000 | Roughly 1.3 million annually |
Data Source: NIH NICHD, Office on Women’s Health (OWH), NIH StatPearls March 2026, Society for Women’s Health Research
The fact that roughly half of all postmenopausal American women have used HRT at least once demonstrates the treatment’s broad historical reach, even during the two decades when the boxed warning suppressed new prescribing. Yet this figure also implies a substantial gap between the number of women experiencing significant menopausal symptoms — estimated at around 90% — and those who ever access hormone therapy, a gap that current federal guidance recommending initiation within 10 years of menopause onset or before age 60 is specifically designed to help close going forward.
With the average age of menopause sitting at 51–52 years and perimenopause itself lasting anywhere from four to ten years, American women are navigating a genuinely long hormonal transition window, during which an estimated 1.3 million women annually cross the menopause threshold. This scale, combined with the recency of the FDA’s regulatory shift, suggests that 2026 prescribing volumes captured in national datasets will likely understate the treatment’s true trajectory, since much of the boxed-warning-driven demand suppression only began lifting in the final months of 2025.
HRT Market Size & Revenue Statistics in US 2026
| Market Metric | Value | Detail |
|---|---|---|
| US HRT Market Revenue (2022) | $7.76 billion | Base year for most current forecasts |
| US HRT Market Projection (2030) | $12.57 billion | 6.2% CAGR from 2023–2030 |
| Global HRT Market (2026) | ~$26.9–$27.6 billion | Figures vary slightly by research firm |
| North America’s Global Market Share | ~38–40% | Largest of any world region |
| Global HRT Market Projection (2033) | $39.4–$42.3 billion | Consistent across multiple market analyses |
| Estrogen & Progesterone Segment Share | ~42–56% | Largest single product category globally |
Data Source: Grand View Research, Precedence Research, Coherent Market Insights, Mordor Intelligence 2026
The US HRT market’s climb from $7.76 billion in 2022 toward a projected $12.57 billion by 2030 reflects steady underlying demand growth even before the 2025 regulatory changes are fully reflected in updated forecasts, meaning near-term revisions to these projections are likely to trend upward rather than down. As the single largest contributor to the global HRT market’s roughly $27 billion 2026 valuation, the US anchors North America’s dominant 38–40% regional share, a position reinforced by the country’s advanced telehealth infrastructure and relatively favorable insurance reimbursement environment for hormone therapies compared with many international markets.
The estrogen and progesterone segment’s dominant 42–56% share of total HRT revenue underscores that menopause-related treatment remains the commercial core of the hormone therapy industry, even as testosterone therapy and human growth hormone segments post faster individual growth rates. With multiple independent market research firms converging on a $39–42 billion global valuation by 2033, the consistency across these projections — despite differing methodologies — lends credibility to the broader growth trajectory even as individual year-by-year figures vary by source.
Menopause & Estrogen Therapy Statistics in US 2026
| Metric | Figure | Detail |
|---|---|---|
| FDA Boxed Warning Removal | November 2025 | Cardiovascular and breast cancer warnings removed |
| Warning Retained | Endometrial cancer (estrogen-only products) | Only remaining labeled risk |
| Elinzanetant (Lynkuet) FDA Approval | October 24, 2025 | Second non-hormonal NK receptor antagonist |
| Fezolinetant (Veozah) FDA Approval | 2023 | First-in-class non-hormonal option |
| Women Experiencing Hot Flashes | 75–82% | During the menopausal transition |
| Postmenopausal Women Projected by 2060 | 90 million | US total, per Bayer/Impacts of Menopause |
Data Source: FDA Drug Alerts & Statements November 2025, Contemporary OB/GYN January 2026, SWAN Study (NIH-funded)
The November 2025 FDA labeling revision represents the most significant regulatory shift in menopausal hormone therapy in over two decades, removing cardiovascular disease and breast cancer warnings while retaining only the endometrial cancer caution specific to estrogen-only formulations. This regulatory recalibration follows years of re-analysis of the original 2002 Women’s Health Initiative data, which researchers now widely agree overstated risks for the age group most commonly prescribed HRT. For a deeper look at how this same regulatory shift has played out among UK healthcare systems, the Estrogen Therapy Statistics in UK report documents a parallel prescribing revival, with UK HRT dispensing having more than doubled since 2018 under similar reassessed risk guidance.
The approval of elinzanetant (Lynkuet) in October 2025, following fezolinetant (Veozah) in 2023, gives American clinicians two genuinely effective non-hormonal options for the 75–82% of women who experience hot flashes during menopause, expanding treatment choice meaningfully beyond hormone therapy alone. With 90 million US women projected to be postmenopausal by 2060, the current wave of regulatory and pharmaceutical innovation arrives at a moment when the addressable patient population is only set to grow substantially over the coming decades.
Testosterone Replacement Therapy Statistics in US 2026
| Metric | Figure | Detail |
|---|---|---|
| US Testosterone Prescriptions (2019) | ~7.3 million | Baseline pre-surge figure |
| US Testosterone Prescriptions (2024) | 11+ million | ~50% increase in five years |
| American Men Over 45 with Hypogonadism | ~40% | Rising to nearly 50% among men in their 80s |
| Hypogonadal Men Who Actually Receive TRT | Only 5%–35% | Reflects longstanding underdiagnosis |
| Military Testosterone Screening Mandate | Ages 30+ | Announced mid-July 2026 by Defense Secretary Hegseth |
| TRT Market Projection by 2032 | $2.9 billion | Growing at a 4.2% CAGR |
Data Source: CBS News 2025 prescription data, SingleCare 2026, American Urological Association, Federal News Network July 2026
The rise from 7.3 million to more than 11 million annual testosterone prescriptions mirrors, in male-specific form, the same broader normalization of hormone therapy sweeping through American healthcare in 2026. This shift now extends even into military policy: the mid-2026 mandate requiring annual testosterone screening for service members aged 30 and older has placed hormone health squarely in the national conversation, even as it draws scrutiny from clinicians who caution that a single blood test cannot reliably diagnose deficiency on its own. For the full breakdown of this policy and its downstream effects on deployment eligibility, the Testosterone Replacement Statistics in US report covers the mandate’s specific screening protocols and TRICARE coverage details in depth.
Despite this surge in prescribing, treatment remains inconsistent relative to actual clinical need: with roughly 40% of American men over 45 meeting criteria for hypogonadism, yet only 5% to 35% of those men actually receiving treatment, a substantial portion of the eligible population remains undiagnosed or untreated. This gap, combined with projections that the US TRT market will reach $2.9 billion by 2032, suggests significant continued room for both clinical and commercial growth in testosterone therapy over the coming years.
HRT Benefits & Clinical Outcomes Statistics in US 2026
| Benefit Metric | Figure | Detail |
|---|---|---|
| TRAVERSE Trial Size | 5,000+ men | Landmark cardiovascular safety study |
| Cardiovascular Risk (TRT vs. Placebo) | No increased risk | Of heart attack or stroke |
| HRT Effectiveness for Vasomotor Symptoms | Most effective treatment available | Per NIH/OWH clinical guidance |
| Women Reporting Improved Sleep on HRT | Majority | Commonly cited clinical outcome |
| Bone Density Protection | Established benefit | HRT reduces osteoporosis-related fracture risk |
| Recommended Treatment Window Benefit | Greatest when started within 10 years of menopause | “Timing hypothesis” supported by current NIH guidance |
Data Source: TRAVERSE trial (New England Journal of Medicine, 2023), NIH/OWH Menopause Treatment guidance, FDA 2025 labeling update
The TRAVERSE trial, involving more than 5,000 men, provided the pivotal safety evidence behind the FDA’s February 2025 removal of testosterone’s cardiovascular black-box warning, confirming that testosterone replacement therapy did not meaningfully increase heart attack or stroke risk compared with placebo. This finding, alongside the 2025 estrogen labeling revision, reflects a broader pattern across US hormone therapy in 2026: accumulating clinical evidence increasingly supports benefits that regulators had previously treated with excessive caution based on older, since-reassessed data.
Beyond cardiovascular safety, HRT remains the single most effective treatment for vasomotor symptoms like hot flashes and night sweats according to current NIH and Office on Women’s Health guidance, while also delivering well-established secondary benefits for bone density protection and sleep quality. The “timing hypothesis” — the clinical principle that benefits are maximized when treatment begins within 10 years of menopause onset or before age 60 — has become a central organizing framework for how American physicians now approach HRT initiation, replacing the more blanket caution that characterized prescribing for much of the previous two decades.
HRT Risks & Safety Statistics in US 2026
| Risk Metric | Figure | Detail |
|---|---|---|
| Elevated Risks Identified in TRAVERSE (Testosterone) | Atrial fibrillation, pulmonary embolism, acute kidney injury | Despite no cardiovascular event increase |
| Retained FDA Warning (Estrogen-Only Products) | Endometrial cancer | Only warning kept after November 2025 revision |
| TRT Fertility Impact | Reduces testicle size and sperm count | AUA and Endocrine Society advise against use when planning children |
| Men on Testosterone Without Formal Diagnosis | Up to 1/3 | Raises questions about unnecessary treatment risk |
| Fezolinetant FDA Warning | Liver injury warning issued | Requires physician consultation and monitoring |
| Deployment Impact of TRT (Military) | Waiver typically required | For service members starting therapy before overseas deployment |
Data Source: TRAVERSE trial, FDA labeling updates 2025, American Urological Association, Endocrine Society guidelines
While the TRAVERSE trial cleared testosterone therapy of major cardiovascular concerns, it simultaneously identified elevated risks of atrial fibrillation, pulmonary embolism, and acute kidney injury, a reminder that the treatment’s improved safety profile is not equivalent to being risk-free. Similarly, on the estrogen side, the retained endometrial cancer warning for estrogen-only products shows that even the most favorable recent regulatory revision preserved genuine, clinically meaningful risk information rather than eliminating caution altogether.
Fertility risk remains one of the clearest and most consistently documented concerns in hormone therapy, with both the American Urological Association and the Endocrine Society explicitly advising against TRT use in men planning to have children, since the therapy reliably reduces testicle size and suppresses sperm production. This risk carries particular weight given that up to a third of current testosterone users were never formally diagnosed with deficiency, meaning a meaningful share of the recent prescribing surge may involve men accepting real fertility and other risks without a confirmed underlying medical need.
HRT Access & Healthcare Statistics in US 2026
| Access Metric | Figure | Detail |
|---|---|---|
| OB/GYN Residency Programs with Menopause Curriculum | Only 31% | Reflects significant training gap |
| OB/GYNs Reporting Feeling Untrained in Menopause Management | ~80% | Estimated national figure |
| Perimenopausal Women Who Discussed Menopause with a Provider | Only 49% | Less than half of symptomatic women |
| Women Who Wait 6+ Months Before Seeking Care | ~50% | Delayed diagnosis remains widespread |
| US Employers Offering Menopause Benefits (2026) | 25% | Up sharply from just 4% in 2023 |
| Annual US Economic Cost of Menopause Symptoms | $26.6 billion | Combining productivity loss and direct medical costs |
Data Source: National Library of Medicine (NCBI/NIH), PwC Women’s Health Report May 2026, Mayo Clinic workplace productivity study
Access to hormone therapy in the US remains constrained less by the treatment’s availability than by structural gaps in medical training and workplace support: with only 31% of OB/GYN residency programs offering formal menopause curriculum and an estimated 80% of OB/GYNs reporting they feel undertrained in menopause management, it follows that barely 49% of perimenopausal women have ever discussed menopause meaningfully with a healthcare provider. This training gap compounds directly into patient outcomes, with roughly half of symptomatic women waiting six months or longer before seeking care at all. A more detailed breakdown of the specific symptom patterns driving these delayed diagnoses, along with the full economic and demographic picture behind the $26.6 billion annual cost estimate, is available in the Perimenopause Symptoms and Treatment report.
The encouraging counterpoint to these access gaps is the rapid growth in employer-sponsored menopause benefits, which jumped from just 4% of US companies in 2023 to 25% in 2026, according to PwC’s most recent Women’s Health Report. This shift signals that American businesses are increasingly recognizing hormone health as a legitimate workforce retention issue rather than a purely private medical matter, even though utilization of these benefits still lags awareness, leaving substantial room for the access gap to narrow further as both employer offerings and general public knowledge continue to expand through the remainder of 2026.
HRT Demographics Statistics in US 2026
| Demographic Metric | Figure | Detail |
|---|---|---|
| Average Age at First HRT Prescription | ~49.8 years | Closely tracks perimenopausal symptom onset |
| Black Women’s Menopause Onset (vs. National Median) | ~2 years earlier | Per NIH-funded SWAN Study |
| Hispanic/Latina Women’s Menopause Onset | ~2 years earlier | Same SWAN Study findings |
| Black Women’s HRT Prescription Rate (vs. White Women) | 26% less likely | Documented in 200,000+ women VA study |
| Hispanic Women’s HRT Prescription Rate (vs. White Women) | 32% less likely | Same VA system study |
| Testosterone Prescribing, Ages 50–64 | 1.57% | Highest prescribing prevalence of any age group |
Data Source: SWAN Study (NIH-funded), Healthline/Menopause Journal VA study 2022, Epic Research Cosmos dataset
Racial and ethnic disparities represent one of the most persistent and well-documented gaps in US hormone therapy access, with both Black and Hispanic women reaching menopause approximately two years earlier than the national median, yet being 26% and 32% less likely, respectively, to be prescribed hormone therapy compared with white women with equivalent symptom profiles. This treatment gap, confirmed across a Veterans Health Administration study of more than 200,000 women, points to systemic inequities in diagnosis and care rather than differences in underlying medical need or symptom severity.
On the male side, testosterone prescribing prevalence peaks among men aged 50 to 64 at 1.57%, the highest rate of any age bracket, even as growth has been fastest proportionally among much younger men in their 20s and early 30s. With the average age at first HRT prescription for women sitting at 49.8 years — closely aligned with typical perimenopausal symptom onset — American clinicians appear to be broadly succeeding at timing treatment appropriately for the patients who do access care, even as the demographic disparities documented above continue to determine which patients reach that point of care in the first place.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.
